Table 2.

Breast Cancer Treatment Profile of Subgroup (n = 29)

Variable	Value	Percentage
Stage of breast cancer
Stage 0 (in situ)	f = 1	3.4%
Stage I	f = 15	51.7%
Stage II	f = 13	44.9%
Treatment for breast cancer
Surgery	f = 28	96.6%
Intravenous chemotherapy	f = 24	82.7%
Radiation	f = 20	69.0%
Months since treatment completed	M = 38.79
	SD = 32.6
Mean months on aromatase inhibitors	M = 25.41
	SD = 13.22
Months on aromatase inhibitors
2 – 12 months	f = 6	20.7%
13 – 24 months	f = 8	27.6%
25 – 36 months	f = 10	34.5%
37 – 48 months	f = 3	10.3%
49 – 53 months	f = 2	6.9%
Type of aromatase inhibitors
letrozole	f = 19	65.50%
exemestane	f = 5	17.25%
anastrazole	f = 5	17.25%
History of tamoxifen use
Yes	f = 25	86.2%
No	f = 4	13.8%
Mean life-time months on tamoxifen	M = 48.44
	SD = 18.65